Transcatheter aortic valve replacement, widely known as TAVR, has fundamentally redefined the treatment of severe aortic stenosis, a progressive narrowing of the heart’s aortic valve that once carried a dismal prognosis for patients too frail to survive open-heart surgery. Rather than replacing the valve through a sternotomy and cardiopulmonary bypass, TAVR delivers a collapsible bioprosthetic valve through a catheter, typically entered at the femoral artery, and positions it within the diseased native valve. The technique has evolved from a salvage therapy for inoperable patients into a standard option across the entire risk spectrum, supported by an accumulating body of randomized trial evidence demonstrating durability and survival benefit comparable to, and in some populations superior to, surgical valve replacement.

The joint statement opens with explicit appreciation for the federal agency’s willingness to modernize its coverage framework. “The American College of Cardiology, the Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography and Interventions appreciate CMS’s efforts to evolve Medicare coverage for TAVR and enhancing access to more patients as the evidence supporting this therapy continues to grow,” the statement declares. For years, patient advocates and clinicians have argued that earlier national coverage determination requirements, which restricted reimbursement largely to facilities meeting specific volume thresholds, created geographic barriers that left many elderly Americans traveling long distances or forgoing treatment altogether for a disease whose five-year untreated survival rivals many advanced cancers.

Yet the societies were equally emphatic that expanded access must not come at the cost of the disciplined, multidisciplinary model that made TAVR one of the most closely studied and carefully monitored therapies in cardiovascular medicine. “As TAVR expands into new patient populations, it is critical to preserve the quality framework that has contributed to its success,” the statement continues. At the center of that framework sits the Heart Team, the collaborative unit of interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiologists, and advanced practice providers who jointly evaluate every candidate for transcatheter therapy. This team-based approach, embedded in professional society guidelines and prior coverage requirements, ensures that each patient receives an individualized assessment of anatomical suitability, procedural risk, and the relative merits of surgical versus catheter-based valve replacement.

The statement identifies several pillars as non-negotiable as coverage evolves: preservation of the Heart Team, continued collaboration across specialties, collection of real-world evidence, systematic outcomes monitoring, and continuous quality improvement. “The preservation of the Heart Team, continued collaboration across specialties, collection of Real-World Evidence, outcomes monitoring, and continuous quality improvement are the foundation of ensuring and improving outcomes for our patients with severe aortic stenosis,” the societies wrote. From a technical standpoint, this vigilance is well founded. TAVR outcomes are highly sensitive to case selection and procedural expertise, with known complications including paravalvular regurgitation, conduction disturbances requiring permanent pacemaker implantation, vascular access injuries, and, in earlier-generation devices, stroke. Careful imaging with computed tomographic angiography and echocardiography, alongside refined valve designs and delivery systems, has steadily reduced these risks, but only within programs that maintain rigorous procedural volume and data review.

Central to the societies’ position is the role of national registries, which have served as the backbone of TAVR surveillance in the United States since the procedure first received approval. “Participation in national registries, externally benchmarked quality programs and rigorous outcomes reporting remain essential to preserving the high standards of care that have defined TAVR’s success,” the statement affirms. The societies committed explicitly to their continued support of the STS/ACC Transcatheter Valve Therapy Registry, the national data infrastructure that captures procedural details, in-hospital outcomes, and longitudinal follow-up for essentially every TAVR performed in American centers. “The societies will continue to support the STS/ACC TVT Registry and other quality initiatives that promote evidence generation, patient safety, continuous improvement and health care value across the cardiovascular community,” they wrote.

The registry model has proven its scientific worth repeatedly. Data drawn from the TVT Registry have informed valve selection strategies, illuminated sex-specific differences in procedural outcomes, quantified real-world rates of pacemaker dependency and readmission, and provided the pragmatic evidence base that regulators have relied upon at each successive expansion of the coverage determination. Observational registry research complements randomized controlled trials by capturing the full heterogeneity of clinical practice, including elderly patients with frailty, bicuspid anatomy, and multimorbidity who are systematically underrepresented in pivotal trials. For a procedure now performed tens of thousands of times annually in the United States, this continuous feedback loop between bedside practice and aggregate data represents one of the most mature examples of learning health system infrastructure in any field of medicine.

The joint statement carries the signatures of the three organizations’ sitting presidents, underscoring the unified front across specialties that have historically approached valve therapy from different vantage points. Roxana Mehran, MD, FACC, president of the American College of Cardiology; Vinay Badhwar, MD, FACS, FACC, president of The Society of Thoracic Surgeons; and J. Dawn Abbott, MD, MSCAI, president of the Society for Cardiovascular Angiography and Interventions, lent their names to a document that deliberately bridges the surgical and interventional communities. That unity is itself noteworthy. Surgical aortic valve replacement remains a durable and appropriate choice for many patients, and the cardiothoracic surgery community has been an essential partner in TAVR’s development rather than a bystander to its rise, co-owning the registries, co-authoring the guidelines, and staffing the Heart Teams at every established program.

The American College of Cardiology, with a membership exceeding 60,000 cardiovascular professionals across more than 140 countries, brings to the effort its extensive registry and accreditation apparatus, including the NCDR family of quality registries. The Society of Thoracic Surgeons, founded in 1964 and representing more than 8,000 cardiothoracic surgeons, researchers, and allied professionals, has long operated its own national surgical databases that pioneered risk-adjusted outcomes reporting in cardiac surgery. The Society for Cardiovascular Angiography and Interventions, established in 1978 as the primary nonprofit society for invasive and interventional cardiology, contributes the procedural expertise of its more than 5,000 members. Together, these organizations collectively steward the educational standards, credentialing pathways, and data systems that determine how TAVR is practiced nationwide.

As Medicare’s revised national coverage determination takes effect, the practical stakes are considerable for patients, hospitals, and the broader trajectory of structural heart intervention. Expanded eligibility promises that more of the growing population of Americans with severe symptomatic aortic stenosis can receive a minimally invasive valve replacement close to home, while the societies’ insistence on Heart Team evaluation, registry participation, and transparent outcomes reporting aims to ensure that the procedure’s impressive evidence-based track record translates faithfully into everyday community practice. The statement ultimately reads less like celebration and more like stewardship: an acknowledgment that a therapy once confined to a handful of pioneering centers has matured into a population-scale treatment, and that the disciplines of measurement, collaboration, and accountability that carried it from first-in-human trials to standard of care must now scale alongside it.

Beyond the immediate policy debate, the statement arrives at a time when the demographic pressure on valve care continues to intensify. Calcific aortic stenosis is fundamentally a disease of aging, driven by progressive leaflet calcification that shares several mechanistic features with atherosclerosis, including lipid accumulation, inflammation, and active bone-like mineral deposition. As life expectancy rises, the prevalence of severe symptomatic disease is expected to grow steadily, placing sustained demand on both surgical and transcatheter capacity and making coverage policy a genuine population health question rather than a narrow reimbursement matter.

The national coverage determination mechanism itself deserves context. Under Medicare rules, CMS must generally decide whether a service is reasonable and necessary for beneficiaries nationwide, and for novel technologies it has historically used coverage with evidence development, linking payment to registry enrollment or clinical study participation. TAVR became one of the most prominent applications of this model, with successive determinations tracking the expanding randomized evidence and conditioning coverage on facility requirements, Heart Team evaluation, and shared decision-making aids that help patients weigh procedural options against their goals of care.

Shared decision making, though less visible than registries, has been a quiet cornerstone of the TAVR quality framework. Because many candidates are elderly and managing multiple chronic conditions, the choice between transcatheter and surgical replacement, or between intervention and conservative management, depends heavily on individual values, frailty, and life circumstances. Formal decision aids and documented patient-physician conversations were built into prior coverage requirements precisely to ensure that expanded access reflects informed patient preference rather than procedural availability alone.

The societies’ emphasis on health care value also reflects a broader shift in cardiovascular policy toward weighing cost against measurable benefit. With TAVR now among the most common valve interventions performed in the United States, even modest differences in complication rates, length of stay, or device selection carry substantial aggregate economic consequences, reinforcing why continued outcomes reporting remains central to the field’s stewardship.

Subject of Research: Medicare national coverage determination for transcatheter aortic valve replacement and the quality standards supporting its expanded use

Article Title: Joint Statement from the American College of Cardiology, The Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography & Interventions on transcatheter aortic valve replacement national coverage determination

Article References: Joint Statement from the American College of Cardiology, The Society of Thoracic Surgeons, and the Society for Cardiovascular Angiography & Interventions on transcatheter aortic valve replacement national coverage determination. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: TAVR, transcatheter aortic valve replacement, Medicare coverage, CMS, aortic stenosis, Heart Team, TVT Registry, American College of Cardiology, Society of Thoracic Surgeons, SCAI, quality monitoring, structural heart disease

Aortic stenosis is the most common valve disease requiring intervention in the aging populations of Europe and North America. As calcium deposits stiffen the aortic valve leaflets, the left ventricle must generate ever higher pressures to push blood through the narrowed orifice. Over time, this chronic pressure overload thickens the ventricular wall, impairs relaxation, and can set off a cascade of downstream consequences, including rising pressures in the left atrium, the pulmonary vasculature, and eventually the right side of the heart. Conventional wisdom has long held that when leakage of the mitral or tricuspid valves—so-called atrioventricular valve regurgitation—appears in patients with severe aortic stenosis, it is simply a late-stage manifestation of this domino effect: a stretched left ventricle distorts the mitral apparatus, pulmonary hypertension burdens the right ventricle, and the tricuspid annulus dilates in response.

The Munich team, led by first author Kornelia Löw and senior author Simon Deseive, challenged that assumption. If atrioventricular valve regurgitation were purely a marker of advanced heart damage, one might expect it to be present before treatment, and one might further expect the relief of the aortic obstruction to halt or even reverse its progression. Instead, the researchers suspected that in many patients, regurgitation of the mitral or tricuspid valve develops as an independent disease entity—driven by its own mechanisms and carrying its own prognostic weight, even after the aortic valve has been successfully replaced.

To test this hypothesis, the investigators assembled a cohort of 1,034 patients with severe aortic stenosis who underwent TAVR at their center between January 2016 and December 2021 and who had no relevant regurgitation of the mitral or tricuspid valves before the procedure. This deliberately “clean baseline” design is what sets the study apart. Previous work on multivalvular disease in TAVR patients has largely focused on those who already had combined lesions at the time of intervention, making it impossible to distinguish pre-existing disease from disease that emerges afterward. By excluding patients with any baseline atrioventricular valve regurgitation, the Munich group could observe, in effect, the natural history of valves left to their own devices once the aortic bottleneck was removed.

The results were unambiguous. During follow-up, 114 patients—11.0 percent of the cohort—developed new mitral and/or tricuspid regurgitation of at least grade 2 severity, the threshold at which leakage becomes clinically relevant. The pattern of involvement was revealing: 75 patients developed isolated mitral regurgitation, 22 developed isolated tricuspid regurgitation, and 17 experienced the combined form. Mitral regurgitation thus dominated the new-onset spectrum, accounting for the majority of cases whether alone or in combination. Echocardiographic assessments, performed according to established guidelines for chamber quantification and valvular regurgitation grading, allowed the team to track valve function over time and to classify severity consistently across the cohort.

The clinical consequences were severe. Patients who developed new atrioventricular valve regurgitation after TAVR had significantly higher three-year all-cause mortality compared with those whose mitral and tricuspid valves remained competent, with a hazard ratio of 1.87 (95 percent confidence interval 1.34–2.61, p < 0.01). The signal was even stronger for cardiovascular mortality, which was significantly elevated in the regurgitation group at p < 0.001. In other words, nearly nine out of ten patients in this cohort avoided new valve leakage after their aortic valve replacement—but for the minority who did not, the development of regurgitation essentially halved the expected survival benefit of the procedure over the following three years.

What might explain this counterintuitive phenomenon? The authors point to several plausible mechanisms. The relief of aortic obstruction changes the loading conditions of the left ventricle abruptly: afterload falls, and the ventricle begins to remodel, sometimes in ways that alter the geometry of the mitral annulus and the tethering forces acting on the leaflets. In some patients, underlying annular dilatation—particularly of the tricuspid annulus—may predate the TAVR procedure but remain hemodynamically silent until subtle shifts in ventricular size, pulmonary pressures, or rhythm unmask it. Atrial fibrillation, which is common in this elderly population and often develops or accelerates after valve intervention, can rapidly enlarge the atria and pull the valve leaflets apart, converting a functionally normal valve into a leaking one. The study’s findings on right ventricular to pulmonary artery coupling, tricuspid annular plane systolic excursion, and stroke volume index—parameters tracked in the analysis—suggest that both left- and right-sided hemodynamics contribute to which patients tip into regurgitation.

The clinical implications are considerable. TAVR volumes are expanding globally, and indications continue to broaden toward younger and lower-risk patients, guided in part by staging classifications of aortic stenosis that incorporate the extent of cardiac damage beyond the valve itself. If more than a tenth of patients without baseline atrioventricular valve disease can be expected to develop significant regurgitation after TAVR—and if that regurgitation carries a nearly twofold increase in mortality—then structured surveillance of the mitral and tricuspid valves after the procedure becomes not an academic nicety but a survival issue. Serial echocardiography, which is already routine in most TAVR follow-up programs, may need to place greater emphasis on quantitative assessment of the atrioventricular valves, and emerging transcatheter therapies for mitral and tricuspid regurgitation may find a new and growing patient population among TAVR survivors.

The study also reframes the interpretation of prior research. Earlier investigations from the same Munich group showed that tricuspid annular dilatation measured by computed tomography predicts both the persistence of tricuspid regurgitation after TAVR and increased two-year mortality, and that the underlying cause of mitral regurgitation influences outcomes after transcatheter aortic valve implantation. Meta-analytic evidence has likewise indicated that improvement of tricuspid regurgitation after TAVR is associated with better survival. Taken together with the new findings, a consistent picture emerges: the atrioventricular valves are not passive bystanders in aortic stenosis but active participants in the disease trajectory, capable of deteriorating independently of the aortic valve and of dragging prognosis down with them.

Several caveats temper the conclusions. The analysis comes from a single high-volume center, and although the cohort of more than a thousand patients is large by the standards of valve research, referral patterns and procedural techniques at LMU Munich may not generalize everywhere. Regurgitation grading by echocardiography remains inherently observer-dependent, particularly for the tricuspid valve, for which no universally accepted quantitative standard exists—a limitation the field has acknowledged in calls for new grading schemes. And as an observational study, the analysis demonstrates association, not causation: new-onset regurgitation may itself be a marker of adverse ventricular remodeling rather than a direct killer. Even so, the strength and consistency of the mortality signal, maintained across both all-cause and cardiovascular endpoints, argue that this is more than statistical noise.

For patients and clinicians alike, the message is one of vigilant follow-up rather than alarm. A successful TAVR remains one of the most effective interventions in modern cardiology, capable of relieving debilitating symptoms and extending life in a population with few alternatives. But the heart is an integrated system, and correcting one valve does not guarantee the health of its neighbors. The Munich study suggests that the mitral and tricuspid valves deserve the same attentive, quantitative scrutiny after aortic valve replacement that the aortic valve itself receives—because in a meaningful minority of patients, the story of valve disease does not end in the catheterization laboratory. It continues, quietly and sometimes lethally, in the valves downstream.